Last reviewed · How we verify
moxifloxacin / dexamethasone
Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, while dexamethasone is a corticosteroid that suppresses inflammation and immune responses.
Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, while dexamethasone is a corticosteroid that suppresses inflammation and immune responses. Used for Bacterial conjunctivitis with inflammation, Post-operative ocular inflammation and infection prophylaxis, Bacterial keratitis with inflammatory component.
At a glance
| Generic name | moxifloxacin / dexamethasone |
|---|---|
| Sponsor | Federal University of São Paulo |
| Drug class | Fluoroquinolone antibiotic + corticosteroid combination |
| Target | Bacterial DNA gyrase, topoisomerase IV, glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Moxifloxacin works by inhibiting bacterial DNA gyrase and topoisomerase IV enzymes, preventing bacterial DNA replication and transcription. Dexamethasone acts as a glucocorticoid receptor agonist, reducing inflammation and immune-mediated tissue damage. This combination targets both the infectious agent and the inflammatory response, commonly used in ophthalmic formulations for bacterial infections with associated inflammation.
Approved indications
- Bacterial conjunctivitis with inflammation
- Post-operative ocular inflammation and infection prophylaxis
- Bacterial keratitis with inflammatory component
Common side effects
- Ocular irritation or discomfort
- Conjunctival hyperemia
- Taste perversion
- Corneal staining
- Increased intraocular pressure (with prolonged corticosteroid use)
Key clinical trials
- PRO-232 in Patients Subjected to Cataract Surgery (PHASE3)
- Study Evaluating PRO-232 an Ophthalmic Solution Compared to Placebo. (PHASE1)
- Dropless Pars Plana Vitrectomy Study (PHASE4)
- Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery (PHASE4)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- Intensified Short Course Regimen for TBM in Adults (PHASE3)
- Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery (PHASE4)
- A Two Chemoprophylaxis Approaches After Phacoemulsification Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- moxifloxacin / dexamethasone CI brief — competitive landscape report
- moxifloxacin / dexamethasone updates RSS · CI watch RSS
- Federal University of São Paulo portfolio CI